Stifel raised the firm’s price target on Zimmer Biomet (ZBH) to $118 from $115 and keeps a Buy rating on the shares following orthopedic surgeon checks on the recent launches of Oxford Cementless and Osseofit. The feedback from doctors is encouraging and indicates broad adoption and growth ahead for Zimmer, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Zimmer Biomet initiated with a Buy at Rothschild & Co Redburn
- Zimmer Biomet Holdings: Operational Improvements and Strategic Positioning Amid Cautious Growth Prospects
- Zimmer Biomet Holdings: Stable Performance with Limited Growth Prospects Justifies Hold Rating
- Zimmer Biomet Issues CHF 600 Million Debt Securities